Stitcher

Stitch Bio is a next-generation therapeutics company pioneering antisense oligonucleotide (ASO) medicines designed to restore normal RNA splicing disrupted by TDP-43 proteinopathy. The company's mission is to repair the transcriptome by correcting cryptic exon inclusion events that occur when TDP-43 function is lost, a central mechanism in neurodegenerative diseases like ALS and Alzheimer's. By utilizing its proprietary platform, Stitch Bio creates precision ASOs that block these harmful insertions and restore functional protein expression. The company's lead program, STIX-01, is currently in pre-clinical development for the treatment of ALS and frontotemporal dementia.